Skip to content
Screener

Celldex Therapeutics CLDX Q4 2025 Annual earnings

Reported February 25, 2026 · Before market open

Revenue$100.0KMiss by $1.2M
EPS-$1.22Miss by $0.22
Revenue estimate$1.3M
EPS estimate-$1.00

Next report

Nov 9, 2026 (in 2 months)
Revenue estimate$722.6K
EPS estimate-$1.02

Financials

Q4 2025

Income statement

See full
Revenue$121.0K-89.7%
Operating income-$87.2M-55.6%
Net income-$81.3M-72.7%
EPS (diluted)-$1.23-73.2%

Balance sheet

See full
Cash & equivalents$28.9M+1.8%
Total debt$2.3M-38.7%
Total equity$527.2M-29.4%
Total assets$583.0M-26.4%

Cash flow

See full
Operating cash flow-$63.9M-96.9%
CapEx$1.3M+69.4%
Free cash flow-$65.2M-96.3%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$1.8B+7.6%
Enterprise value$1.78B+7.6%
P/S1,167.4×+929×

Profitability

See full
Operating margin-18,587.7%-22,552pp
Net margin-16,737.2%-19,812pp
FCF margin-13,820.1%-17,211pp

Returns & leverage

See full
Return on equity-40.6%+42.8pp
Debt / equity0×0.0×
Current ratio10.5×-8.4×

Segments

By product

See full
Grant$48.0K-95.9%
Service$40.0K+400%

FAQ

When did Celldex Therapeutics report Q4 2025 earnings?
Celldex Therapeutics (CLDX) reported Q4 2025 earnings on February 25, 2026 before market open.
What were Celldex Therapeutics's Q4 2025 revenue and EPS?
Celldex Therapeutics reported revenue of $100.0K and eps of $-1.22 for Q4 2025.
Did Celldex Therapeutics beat estimates in Q4 2025?
Revenue missed the consensus estimate of $1.3M by $1.2M. EPS missed the consensus estimate of $-1.00 by $0.22.
How did Celldex Therapeutics's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 91.5% from $1.2M a year earlier and eps declined 71.8% from $-0.71.
Where can I find Celldex Therapeutics's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001171843-26-001098) and the 10-K periodic report (0001104659-26-019652) directly on SEC EDGAR. The filing index links above go to sec.gov.